bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 2 from HDM2 Regulation by AURKA Promotes Cell Survival in Gastric Cancer
Authors: Sehdev Vikas , Katsha Ahmed , Arras Janet , Peng Dunfa , Soutto Mohammed , Ecsedy Jeffrey , Zaika Alexander , Belkhiri Abbes , El-Rifai Wael
Published: April 2023

PDF file 1423K, AURKA regulates HDM2 through an AKT-independent mechanism
Supplementary Methods, Figure Legend from Targeting Protein Kinase CK2 Suppresses Prosurvival Signaling Pathways and Growth of Glioblastoma
Authors: Zheng Ying , McFarland Braden C. , Drygin Denis , Yu Hao , Bellis Susan L. , Kim Hyunsoo , Bredel Markus , Benveniste Etty N.
Published: April 2023

PDF file - 82K
Supplementary Figure 6 from Targeting Protein Kinase CK2 Suppresses Prosurvival Signaling Pathways and Growth of Glioblastoma
Authors: Zheng Ying , McFarland Braden C. , Drygin Denis , Yu Hao , Bellis Susan L. , Kim Hyunsoo , Bredel Markus , Benveniste Etty N.
Published: April 2023

PDF file - 68K, Supplemental Figure 6. Occurrence of Senescence in CX-4945-treated GBM Cells.
Supplementary Figure 4 from Targeting Protein Kinase CK2 Suppresses Prosurvival Signaling Pathways and Growth of Glioblastoma
Authors: Zheng Ying , McFarland Braden C. , Drygin Denis , Yu Hao , Bellis Susan L. , Kim Hyunsoo , Bredel Markus , Benveniste Etty N.
Published: April 2023

PDF file - 90K, Supplemental Figure 4. Effect of CX-4945 on GBM Cell Integrin Expression and Morphology is Reversible.
Supplementary Figure 4 from Inhibition of NF-κB–Mediated Signaling by the Cyclin-Dependent Kinase Inhibitor CR8 Overcomes Prosurvival Stimuli to Induce Apoptosis in Chronic Lymphocytic Leukemia Cells
Authors: Cosimo Emilio , McCaig Alison M. , Carter-Brzezinski Luke J.M. , Wheadon Helen , Leach Michael T. , Le Ster Karine , Berthou Christian , Durieu Emilie , Oumata Nassima , Galons Hervé , Meijer Laurent , Michie Alison M.
Published: April 2023

PDF file - 55K, CR8 selectively induces apoptosis in CLL cells compared with healthy PBMCs upon co-culture with the NT-L cell line.
Supplementary Figure 2 from Inhibition of NF-κB–Mediated Signaling by the Cyclin-Dependent Kinase Inhibitor CR8 Overcomes Prosurvival Stimuli to Induce Apoptosis in Chronic Lymphocytic Leukemia Cells
Authors: Cosimo Emilio , McCaig Alison M. , Carter-Brzezinski Luke J.M. , Wheadon Helen , Leach Michael T. , Le Ster Karine , Berthou Christian , Durieu Emilie , Oumata Nassima , Galons Hervé , Meijer Laurent , Michie Alison M.
Published: April 2023

PDF file - 48K, Viability of previously-cryopreserved PBMCs from healthy donors upon treatment with CR8.
Supplementary Figure 1 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
Authors: Zaid Tarrik M. , Yeung Tsz-Lun , Thompson Melissa S. , Leung Cecilia S. , Harding Tom , Co Ngai-Na , Schmandt Rosie S. , Kwan Suet-Ying , Rodriguez-Aguay Cristian , Lopez-Berestein Gabriel , Sood Anil K. , Wong Kwong-Kwok , Birrer Michael J. , Mok Samuel C.
Published: April 2023

PDF file - 2929K, FGFR4 silencing in ovarian cancer cells by siRNA transfection
Supplementary Figure Legend from Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer
Authors: Horak Christine E. , Pusztai Lajos , Xing Guan , Trifan Ovidiu C. , Saura Cristina , Tseng Ling-Ming , Chan Stephen , Welcher Rosanne , Liu David
Published: April 2023

PDF file - 68K
Supplementary Figure Legend from Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection
Authors: Collinson Fiona , Hutchinson Michelle , Craven Rachel A. , Cairns David A. , Zougman Alexandre , Wind Tobias C. , Gahir Narinder , Messenger Michael P. , Jackson Sharon , Thompson Douglas , Adusei Cybil , Ledermann Jonathan A. , Hall Geoffrey , Jayson Gordon C. , Selby Peter J. , Banks Rosamonde E.
Published: April 2023

PDF file - 58K
Supplementary Figure 6 from Ethacrynic Acid and a Derivative Enhance Apoptosis in Arsenic Trioxide–Treated Myeloid Leukemia and Lymphoma Cells: The Role of Glutathione S-Transferase P1-1
Authors: Wang Rui , Liu Changda , Xia Lijuan , Zhao Guisen , Gabrilove Janice , Waxman Samuel , Jing Yongkui
Published: April 2023

PDF file - 90K, GSH depletion and apoptosis induction in Jurkat cells
Supplementary Table 2 from Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer
Authors: Patani Neill , Dunbier Anita K. , Anderson Helen , Ghazoui Zara , Ribas Ricardo , Anderson Elizabeth , Gao Qiong , A'hern Roger , Mackay Alan , Lindemann Justin , Wellings Robert , Walker Jill , Kuter Irene , Martin Lesley-Ann , Dowsett Mitch
Published: April 2023

XLSX file - 1531KB, Details of transcripts and Gene Ontology (GO) functional sets resulting from comparative analyses. Probes are annotated with gene symbols where available.
Supplementary Table 3 from Clonal Evolution, Genomic Drivers, and Effects of Therapy in Chronic Lymphocytic Leukemia
Authors: Ouillette Peter , Saiya-Cork Kamlai , Seymour Erlene , Li Cheng , Shedden Kerby , Malek Sami N.
Published: April 2023

XLSX file - 18K, Listing of gene mutations and aCNA/LOH/cn-LOH in CLL samples analyzed at enrollment and at longitudinal time points that demonstrated changes. Listing of genes located in small minimally altered regions.
Supplementary Table 1 from Notch Pathway Activity Identifies Cells with Cancer Stem Cell–like Properties and Correlates with Worse Survival in Lung Adenocarcinoma
Authors: Hassan Khaled A. , Wang Luo , Korkaya Hasan , Chen Guoan , Maillard Ivan , Beer David G. , Kalemkerian Gregory P. , Wicha Max S.
Published: April 2023

PDF file - 76K, Clinical variables of the lung adenocarcinoma patients.
Supplementary Table S6 from Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors
Authors: Vrignaud Patricia , Sémiond Dorothée , Lejeune Pascale , Bouchard Hervé , Calvet Loreley , Combeau Cecile , Riou Jean-François , Commerçon Alain , Lavelle François , Bissery Marie-Christine
Published: April 2023

Supplementary Table S6 - PDF file 10K PDF, Median tumor volumes � interquartile ranges following treatment with cabazitaxel and docetaxel in female nude mice bearing human gastric N87 tumor xenografts
Supplementary Figure 3 from miR-187 Is an Independent Prognostic Factor in Breast Cancer and Confers Increased Invasive Potential In Vitro
Authors: Mulrane Laoighse , Madden Stephen F. , Brennan Donal J. , Gremel Gabriela , McGee Sharon F. , McNally Sara , Martin Finian , Crown John P. , Jirström Karin , Higgins Desmond G. , Gallagher William M. , O'Connor Darran P.
Published: April 2023

PDF file - 757K, Ectopic expression of miR187 in SBKR3 cells, phenotypic effects
Supplementary Table S2 from A Panel of Three Markers Hyper- and Hypomethylated in Urine Sediments Accurately Predicts Bladder Cancer Recurrence
Authors: Su Sheng-Fang , de Castro Abreu André Luís , Chihara Yoshitomo , Tsai Yvonne , Andreu-Vieyra Claudia , Daneshmand Siamak , Skinner Eila C. , Jones Peter A. , Siegmund Kimberly D. , Liang Gangning
Published: April 2023

Primer sequences used in pyrosequencing.
Supplementary Figure 3 from Antibody-Mediated Delivery of Anti–KRAS-siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer
Authors: Bäumer Sebastian , Bäumer Nicole , Appel Neele , Terheyden Lisa , Fremerey Julia , Schelhaas Sonja , Wardelmann Eva , Buchholz Frank , Berdel Wolfgang E. , Müller-Tidow Carsten
Published: April 2023

Supplementary Figure 3. MTS assay of SW620 cells.
Supplementary Figure S3 from A Panel of Three Markers Hyper- and Hypomethylated in Urine Sediments Accurately Predicts Bladder Cancer Recurrence
Authors: Su Sheng-Fang , de Castro Abreu André Luís , Chihara Yoshitomo , Tsai Yvonne , Andreu-Vieyra Claudia , Daneshmand Siamak , Skinner Eila C. , Jones Peter A. , Siegmund Kimberly D. , Liang Gangning
Published: April 2023

Receiver operating characteristic (ROC) curves of the three-marker signature in detecting tumor recurrence.
Supplementary Figure S1 from A Panel of Three Markers Hyper- and Hypomethylated in Urine Sediments Accurately Predicts Bladder Cancer Recurrence
Authors: Su Sheng-Fang , de Castro Abreu André Luís , Chihara Yoshitomo , Tsai Yvonne , Andreu-Vieyra Claudia , Daneshmand Siamak , Skinner Eila C. , Jones Peter A. , Siegmund Kimberly D. , Liang Gangning
Published: April 2023

DNA methylation alterations can be detected in urine sediment samples from patients with bladder cancer.
Supplementary Table 5 from Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
Authors: Saura Cristina , Bendell Johanna , Jerusalem Guy , Su Shaun , Ru Qinhua , De Buck Stefan , Mills David , Ruquet Sophie , Bosch Ana , Urruticoechea Ander , Beck Joseph T. , Di Tomaso Emmanuelle , Sternberg David W. , Massacesi Cristian , Hirawat Samit , Dirix Luc , Baselga Jose
Published: April 2023

PDF file - 42K, Summary of deaths and adverse events (safety set).
Supplementary Figures 1 - 6 from microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters
Authors: Negrini Massimo , Cutrona Giovanna , Bassi Cristian , Fabris Sonia , Zagatti Barbara , Colombo Monica , Ferracin Manuela , D'Abundo Lucilla , Saccenti Elena , Matis Serena , Lionetti Marta , Agnelli Luca , Gentile Massimo , Recchia Anna Grazia , Bossio Sabrina , Reverberi Daniele , Rigolin Gianmatteo , Calin George A. , Sabbioni Silvia , Russo Giandomenico , Tassone Pierfrancesco , Morabito Fortunato , Ferrarini Manlio , Neri Antonino
Published: April 2023

PDF file - 1024K, Supplementary Figure 1. Purification of normal human B cell subset populations. Supplementary Figure 2. CLL miRNA expression profile is homogeneous and distinct from multiple myeloma and Sezary syndrome. Supplementary Figure 3. Quantitative PCR validation of miRNAs differentially expressed between CLL and normal memory B cells. Supplementary Figure 4. Expression of miR-29c* in M-CLL and UM-CLL. Supplementary Figure 5. Validation of some miRNAs differentially expressed in IGHV or FISH classes. Supplementary Figure 6. Cluster analysis of averaged miRNA expression in the different FISH subgroups of CLL.
Supplementary Table 5 from Next-Generation Sequencing of Translocation Renal Cell Carcinoma Reveals Novel RNA Splicing Partners and Frequent Mutations of Chromatin-Remodeling Genes
Authors: Malouf Gabriel G. , Su Xiaoping , Yao Hui , Gao Jianjun , Xiong Liangwen , He Qiuming , Compérat Eva , Couturier Jérôme , Molinié Vincent , Escudier Bernard , Camparo Philippe , Doss Denaha J. , Thompson Erika J. , Khayat David , Wood Christopher G. , Yu Willie , Teh Bin T. , Weinstein John , Tannir Nizar M.
Published: April 2023

XLSX file - 10K, List of all ccRCC included from the TCGA with the identified translocations in each sample.
Supplementary Methods from PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Authors: Chen Benjamin J. , Chapuy Bjoern , Ouyang Jing , Sun Heather H. , Roemer Margaretha G.M. , Xu Mina L. , Yu Hongbo , Fletcher Christopher D.M. , Freeman Gordon J. , Shipp Margaret A. , Rodig Scott J.
Published: April 2023

PDF file - 56K
Table S1 from MicroRNA Array Analysis Finds Elevated Serum miR-1290 Accurately Distinguishes Patients with Low-Stage Pancreatic Cancer from Healthy and Disease Controls
Authors: Li Ang , Yu Jun , Kim Haeryoung , Wolfgang Christopher L. , Canto Marcia Irene , Hruban Ralph H. , Goggins Michael
Published: April 2023

Table S1 - XLSX file 11K, Supplemental Table S1. Demographics or pathologic characteristics of patients with pancreatic cnacer and controls
Supplementary Figure 6 from Role of Hedgehog Signaling in Malignant Pleural Mesothelioma
Authors: Shi Yandong , Moura Ubiratan , Opitz Isabelle , Soltermann Alex , Rehrauer Hubert , Thies Svenja , Weder Walter , Stahel Rolf A. , Felley-Bosco Emanuela
Published: April 2023

PDF file, 66K, Western blot analysis of NF2 protein in SDM103T, ZL55SPT cells. SDM71 cells were used as positive control (1). 1. Thurneysen C, Opitz I, Kurtz S, Weder W, Stahel RA, Felley-Bosco E. Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer. 2009;64:140-7.
Figure S3 from Immunomodulatory Monoclonal Antibodies Combined with Peptide Vaccination Provide Potent Immunotherapy in an Aggressive Murine Neuroblastoma Model
Authors: Williams Emily L. , Dunn Stuart N. , James Sonya , Johnson Peter W. , Cragg Mark S. , Glennie Martin J. , Gray Juliet C.
Published: April 2023

Figure S3 - PDF file 113K, Figure S3. Tumor growth is abrogated after anti-CTLA-4 and GWEPDDNPI therapy. Mice were injected s.c. with 2 x 106 AgN2a (A) or NXS2 (B) neuroblastoma cells. Tumour growth was monitored throughout and the average of two perpendicular measurements was determined. Mice were culled when tumour size reached greater than 225 mm2. Data represents an example of three experiments, where n = 5 mice / group
Figure S2 from Immunomodulatory Monoclonal Antibodies Combined with Peptide Vaccination Provide Potent Immunotherapy in an Aggressive Murine Neuroblastoma Model
Authors: Williams Emily L. , Dunn Stuart N. , James Sonya , Johnson Peter W. , Cragg Mark S. , Glennie Martin J. , Gray Juliet C.
Published: April 2023

Figure S2 - PDF file 115K, Figure S2. Co-modulatory antibodies have no direct in vitro effect on cell death or proliferation. Neuro2a, NXS2, AgN2a and A20 cell lines were grown in vitro and incubated with anti-4-1BB LOB12.3), anti-CD40 (3/23) or anti-CTLA-4 (UC10 4F10-11) mAb at concentrations shown. A, 3H thymidine incorporation in final 16 hr of 48 hr incubation. Similar results were seen at 24 hr. B, % viable tumor cells (relative to control, untreated cells) as determined by Annexin V / PI staining after 24 hr of culture. Data represents triplicate results from three experiments. Error is expressed as SEM
Figure S1 from Immunomodulatory Monoclonal Antibodies Combined with Peptide Vaccination Provide Potent Immunotherapy in an Aggressive Murine Neuroblastoma Model
Authors: Williams Emily L. , Dunn Stuart N. , James Sonya , Johnson Peter W. , Cragg Mark S. , Glennie Martin J. , Gray Juliet C.
Published: April 2023

Figure S1 - PDF file 105K, Figure S1. Neuroblastoma cell lines do not express 4-1BB, CD40 or CTLA-4. The expression of 4-1BB, CD40 and CTLA-4 on naive and activated splenocytes (0.5 mg anti-CD3 i.v. 48 hr) and the neuroblastoma cell lines was determined by indirect flow cytometry. Cells were incubated with 10 microg/ml unlabelled mAb, either isotype control (Mc39/16) anti-4-1BB (LOB12.3), anti-CD40 (3/23) or anti-CTLA-4 (UC10 4F10-11) prior to washing and incubation with PE-conjugated anti-mouse Fc. Expression of 4-1BB, CD40 and CTLA-4 could be observed on T-cells from activated splenocytes, but not on naive T-cells as expected. Expression of 4-1BB, CD40 and CTLA-4 was not evident on Neuro2a, AgN2a or NXS2 cell lines. Data represents an example of three experiments
Supplementary Tables 1 - 5 from A New Approach to Simultaneously Quantify Both TCR α- and β-Chain Diversity after Adoptive Immunotherapy
Authors: Zhang Minying , Maiti Sourindra , Bernatchez Chantale , Huls Helen , Rabinovich Brian , Champlin Richard E. , Vence Luis M. , Hwu Patrick , Radvanyi Laszlo , Cooper Laurence J.N.
Published: April 2023

PDF file, 111K, Supplementary Table S1. Samples from 14 patients that received autologous TILs were studied. Supplementary Table S2.TCR Vα primers (the first 50 nt) and probes (the last 50 nt)used for DTEA analysis. Supplementary Table S3. TCR Vβ primers (the first 50 nt) and probes (the last 50 nt)used for DTEA analysis. Supplementary Table S4. House keeping genes used in DTEA analysis. Supplementary Table S5. DTEA can detect the low-frequency TCRVβ genes that cannot be readily identified by classical cloning.
Supplementary Figure 3. Selected RPPA data from Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47)
Authors: Slingluff Craig L. , Petroni Gina R. , Molhoek Kerrington R. , Brautigan David L. , Chianese-Bullock Kimberly A. , Shada Amber L. , Smolkin Mark E. , Olson Walter C. , Gaucher Alison , Chase Cheryl Murphy , Grosh William W. , Weiss Geoffrey R. , Wagenseller Aubrey G. , Olszanski Anthony J. , Martin Lainie , Shea Sofia M. , Erdag Gulsun , Ram Prahlad , Gershenwald Jeffrey E. , Weber Michael J.
Published: April 2023

Detailed data are shown for selected proteins assayed by RPPA.
Supplementary Table 2 from A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non–Small Cell Lung Cancer Patients
Authors: Tang Hao , Xiao Guanghua , Behrens Carmen , Schiller Joan , Allen Jeffrey , Chow Chi-Wan , Suraokar Milind , Corvalan Alejandro , Mao Jianhua , White Michael A. , Wistuba Ignacio I. , Minna John D. , Xie Yang
Published: April 2023

PDF file - 64K, Meta-analysis of 18-hub-gene prognostic signature on ADC patients and SCC patients.
Supplementary Table 1 from A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non–Small Cell Lung Cancer Patients
Authors: Tang Hao , Xiao Guanghua , Behrens Carmen , Schiller Joan , Allen Jeffrey , Chow Chi-Wan , Suraokar Milind , Corvalan Alejandro , Mao Jianhua , White Michael A. , Wistuba Ignacio I. , Minna John D. , Xie Yang
Published: April 2023

PDF file - 49K, Multivariate Cox regression analysis of the 18-hub-gene prognostic signature and clinical variables in the UT Lung SPORE.
Supplemental Table 2 from Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing
Authors: Jia Jingquan , Dellinger Andrew E. , Weiss Eric S. , Bulusu Anuradha , Rushing Christel , Li Haiyan , Howard Leigh A. , Kaplan Neal , Pang Herbert , Hurwitz Herbert I. , Nixon Andrew B.
Published: April 2023

Supplemental Table 2. BEE study patients and the number of patients whose granulation tissue biopsies were available for biomarker study.
Supplemental Table 1 from Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing
Authors: Jia Jingquan , Dellinger Andrew E. , Weiss Eric S. , Bulusu Anuradha , Rushing Christel , Li Haiyan , Howard Leigh A. , Kaplan Neal , Pang Herbert , Hurwitz Herbert I. , Nixon Andrew B.
Published: April 2023

Supplemental Table 1. Characteristics of patients whose granulation tissue biopsies were available for biomarker analysis and patients whose average vascular score (AVS) were available.
Supplementary Figure 2 from BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
Authors: Liu Chengwen , Peng Weiyi , Xu Chunyu , Lou Yanyan , Zhang Minying , Wargo Jennifer A. , Chen Jie Qing , Li Haiyan S. , Watowich Stephanie S. , Yang Yan , Frederick Dennie Tompers , Cooper Zachary A. , Mbofung Rina M. , Whittington Mayra , Flaherty Keith T. , Woodman Scott E. , Davies Michael A. , Radvanyi Laszlo G. , Overwijk Willem W. , Lizée Gregory , Hwu Patrick
Published: April 2023

PDF file - 26K, Chromium release assay
Data Supplement from Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts
Authors: Suryani Santi , Carol Hernan , Chonghaile Triona Ni , Frismantas Viktoras , Sarmah Chintanu , High Laura , Bornhauser Beat , Cowley Mark J. , Szymanska Barbara , Evans Kathryn , Boehm Ingrid , Tonna Elise , Jones Luke , Manesh Donya Moradi , Kurmasheva Raushan T. , Billups Catherine , Kaplan Warren , Letai Anthony , Bourquin Jean-Pierre , Houghton Peter J. , Smith Malcolm A. , Lock Richard B.
Published: April 2023

Supplementary Figure S1. Examples of flow cytometry data analysis for in vitro cytotoxicity co-culture assay.
Data Supplement from Association of EGFR Expression Level and Cetuximab Activity in Patient-Derived Xenograft Models of Human Non–Small Cell Lung Cancer
Authors: Amendt Christiane , Staub Eike , Friese-Hamim Manja , Störkel Stephan , Stroh Christopher
Published: April 2023

Table S2. Mann-Whitney test P-values relating to the differences in log2 tumor/control ratios at week 3 for cetuximab monotherapy/control and cisplatin plus cetuximab/cisplatin alone between tumors with low and high EGFR expression as determined by different EGFR immunohistochemistry score thresholds.
supplemental figure and table legend from Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups
Authors: Merino Diana M. , Shlien Adam , Villani Anita , Pienkowska Malgorzata , Mack Stephen , Ramaswamy Vijay , Shih David , Tatevossian Ruth , Novokmet Ana , Choufani Sanaa , Dvir Rina , Ben-Arush Myran , Harris Brent T. , Hwang Eugene I. , Lulla Rishi , Pfister Stefan M. , Achatz Maria Isabel , Jabado Nada , Finlay Jonathan L. , Weksberg Rosanna , Bouffet Eric , Hawkins Cynthia , Taylor Michael D. , Tabori Uri , Ellison David W. , Gilbertson Richard J. , Malkin David
Published: April 2023

supplemental figure and table legend
Figure S2 from Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups
Authors: Merino Diana M. , Shlien Adam , Villani Anita , Pienkowska Malgorzata , Mack Stephen , Ramaswamy Vijay , Shih David , Tatevossian Ruth , Novokmet Ana , Choufani Sanaa , Dvir Rina , Ben-Arush Myran , Harris Brent T. , Hwang Eugene I. , Lulla Rishi , Pfister Stefan M. , Achatz Maria Isabel , Jabado Nada , Finlay Jonathan L. , Weksberg Rosanna , Bouffet Eric , Hawkins Cynthia , Taylor Michael D. , Tabori Uri , Ellison David W. , Gilbertson Richard J. , Malkin David
Published: April 2023

Figure S2. Unsupervised clustering analysis of CPTs showed significant segregation of CPCs from CPPs with aCPPs (subgroups delineated by red rectangles p=0·05). Clustering was performed using PVCLUST and 1000 gene expression normalized intensities and methylation Beta values with the largest MAD. Colors: Red: CPC, Yellow: CPP, Light blue: aCPP
Supplementary Table S3 from Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Authors: Frantzi Maria , van Kessel Kim E. , Zwarthoff Ellen C. , Marquez Mirari , Rava Marta , Malats Núria , Merseburger Axel S. , Katafigiotis Ioannis , Stravodimos Konstantinos , Mullen William , Zoidakis Jerome , Makridakis Manousos , Pejchinovski Martin , Critselis Elena , Lichtinghagen Ralph , Brand Korbinian , Dakna Mohammed , Roubelakis Maria G. , Theodorescu Dan , Vlahou Antonia , Mischak Harald , Anagnou Nicholas P.
Published: April 2023

Supplementary Table S3. Shortlist of significant biomarkers, as derived based on statistical analysis between primary UBC cases (n=341) and urological controls (n=110) - including negative after cystoscopy samples, samples from patients with hematuria and patients with benign urological diseases. Wilcoxon test was applied to assess the significant differences. The significant biomarkers were subsequently compared for their trend of regulation among the different centers. Only those that were identified with the same regulation in at least two clinical centres were further considered for the generation of the peptide biomarker model.
Figure S5 from Glycodelin: A New Biomarker with Immunomodulatory Functions in Non–Small Cell Lung Cancer
Authors: Schneider Marc A. , Granzow Martin , Warth Arne , Schnabel Philipp A. , Thomas Michael , Herth Felix J.F. , Dienemann Hendrik , Muley Thomas , Meister Michael
Published: April 2023

Figure S5. Different controls of experiments.
Supplementary Methods, Figures 1 - 2, Tables 1 - 2 from Old Drug New Use—Amoxapine and Its Metabolites as Potent Bacterial β-Glucuronidase Inhibitors for Alleviating Cancer Drug Toxicity
Authors: Kong Ren , Liu Timothy , Zhu Xiaoping , Ahmad Syed , Williams Alfred L. , Phan Alexandria T. , Zhao Hong , Scott John E. , Yeh Li-An , Wong Stephen T.C.
Published: April 2023

PDF file - 506KB, Supp. Fig. S1 2D structures of Amoxapine, Amoxapine's metabolites, Loxapine, and the previous reported potent GUS inhibitors - Inhibitor 1 and 2. Suppl. Fig. S2 The initial structures (left panel, Before MD) and the last snapshots (right panel, After MD) taken from 4 ns MD simulation. Supp. Table S1. Hydrogen bonds formed by ligand and protein during the last 2 ns simulation. Supp. Table. S2 Histologic score and Ki-67-positive cells of the examined tissue.
Supplemental Figure 2 from MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro
Authors: Angell Trevor E. , Lechner Melissa G. , Jang Julie K. , LoPresti Jonathan S. , Epstein Alan L.
Published: April 2023

Supplemental Figure 2. Peripheral blood leukocyte controls for tumor cell line co-cultures showing baseline and increased IL-2 production and T cell activation after CD3/CD28 stimulation. Healthy donor peripheral blood leukocytes (PBL) were cultured alone in the presence or absence of anti-CD3/CD28 stimulation beads, as experimental controls for tumor cell line-PBL co-cultures. Mean (n=4) IL-2 production and T cell activation (percent CD25+ of CD3+ T-cells) is shown.
Supplementary Table S4 from The Ability of Bilirubin in Identifying Smokers with Higher Risk of Lung Cancer: A Large Cohort Study in Conjunction with Global Metabolomic Profiling
Authors: Wen Chi-Pang , Zhang Fanmao , Liang Dong , Wen Christopher , Gu Jian , Skinner Heath , Chow Wong-Ho , Ye Yuanqing , Pu Xia , Hildebrandt Michelle A.T. , Huang Maosheng , Chen Chien-Hua , Hsiung Chao Agnes , Tsai Min Kuang , Tsao Chwen Keng , Lippman Scott M. , Wu Xifeng
Published: April 2023

Supplementary Table S4. Correlation between the levels detected by the metabolomic profiling and the individual metabolite validation by LC-MS/MS
Supplementary Table S2 from The Ability of Bilirubin in Identifying Smokers with Higher Risk of Lung Cancer: A Large Cohort Study in Conjunction with Global Metabolomic Profiling
Authors: Wen Chi-Pang , Zhang Fanmao , Liang Dong , Wen Christopher , Gu Jian , Skinner Heath , Chow Wong-Ho , Ye Yuanqing , Pu Xia , Hildebrandt Michelle A.T. , Huang Maosheng , Chen Chien-Hua , Hsiung Chao Agnes , Tsai Min Kuang , Tsao Chwen Keng , Lippman Scott M. , Wu Xifeng
Published: April 2023

Supplementary Table S2. List of metabolites passing QC
Supplementary Table S1 from The Ability of Bilirubin in Identifying Smokers with Higher Risk of Lung Cancer: A Large Cohort Study in Conjunction with Global Metabolomic Profiling
Authors: Wen Chi-Pang , Zhang Fanmao , Liang Dong , Wen Christopher , Gu Jian , Skinner Heath , Chow Wong-Ho , Ye Yuanqing , Pu Xia , Hildebrandt Michelle A.T. , Huang Maosheng , Chen Chien-Hua , Hsiung Chao Agnes , Tsai Min Kuang , Tsao Chwen Keng , Lippman Scott M. , Wu Xifeng
Published: April 2023

Supplementary Table S1. Host characteristics of study population
Supplementary Figure S3 from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma
Authors: Pokorny Jenny L. , Calligaris David , Gupta Shiv K. , Iyekegbe Dennis O. , Mueller Dustin , Bakken Katrina K. , Carlson Brett L. , Schroeder Mark A. , Evans Debra L. , Lou Zhenkun , Decker Paul A. , Eckel-Passow Jeanette E. , Pucci Vincenzo , Ma Bennett , Shumway Stuart D. , Elmquist William F. , Agar Nathalie Y.R. , Sarkaria Jann N.
Published: April 2023

Supplementary Figure S3. Growth inhibition in GBM6, 12 or 22 in response to graded concentrations of MK-1775, TMZ or their combination as assessed by neurosphere formation
Supplementary Figure S1 from The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma
Authors: Pokorny Jenny L. , Calligaris David , Gupta Shiv K. , Iyekegbe Dennis O. , Mueller Dustin , Bakken Katrina K. , Carlson Brett L. , Schroeder Mark A. , Evans Debra L. , Lou Zhenkun , Decker Paul A. , Eckel-Passow Jeanette E. , Pucci Vincenzo , Ma Bennett , Shumway Stuart D. , Elmquist William F. , Agar Nathalie Y.R. , Sarkaria Jann N.
Published: April 2023

Supplementary Figure S1. Relative quantification of Wee1 transcript in GBM xenograft lines
Supplemental Table S1 from On-Target Effect of FK866, a Nicotinamide Phosphoribosyl Transferase Inhibitor, by Apoptosis-Mediated Death in Chronic Lymphocytic Leukemia Cells
Authors: Gehrke Iris , Bouchard Eric D.J. , Beiggi Sara , Poeppl Armando G. , Johnston James B. , Gibson Spencer B. , Banerji Versha
Published: April 2023

Table S1: Data was provided by the Manitoba Blood and Marrow Tumor Bank. Positive Zap-70 status refers to presence of Zap-70 on 20% or more of CLL cells. Positive CD38 status refers to presence of CD38 on 30% or more of CLL cells. Treatment status labeled with (*) indicates relapse. WBC: white blood cell count, f: female, m: male, IgVh: immunoglobulin variable heavy chain, M: mutated, UM: unmutated, LDT: lymphocyte doubling time, B2M: β2-microglobulin, Ofa: Ofatumumab, Benda: Bendamustine, RCD: Rituximab/Cyclophosphamide/Dexamethasone, FR: Fludarabine/Rituximab, Chlora: Chlorambucil, RC: Rituximab/Cyclophosphamide, FCR: Fludarabine/Cyclophosphamide/Rituximab, FAlem: Fludarabine/Alemtuzumab, Alem: Alemtuzumab, Pred: Prednisone, Allo sct: allogeneic stem cell transplant, CD: Cyclophosphamide/Dexamethasone, CRD: Cyclophosphamide/Rituximab/ Dexamethasone, LD50: lethal dose 50, FDC: fraction of dead cells, nd: not determined
Supplementary Table 3 from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
Authors: Holkova Beata , Supko Jeffrey G. , Ames Matthew M. , Reid Joel M. , Shapiro Geoffrey I. , Perkins Edward Brent , Ramakrishnan Viswanathan , Tombes Mary Beth , Honeycutt Connie , McGovern Renee M. , Kmieciak Maciej , Shrader Ellen , Wellons Martha D. , Sankala Heidi , Doyle Austin , Wright John , Roberts John D. , Grant Steven
Published: April 2023

PDF file - 41K, Pharmacokinetic parameters of vorinostat and its major metabolites.
Supplementary Tables 1-5 from Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients
Authors: Carlino Matteo S. , Fung Carina , Shahheydari Hamideh , Todd Jason R. , Boyd Suzanah C. , Irvine Mal , Nagrial Adnan M. , Scolyer Richard A. , Kefford Richard F. , Long Georgina V. , Rizos Helen
Published: April 2023

Supplementary Tables 1-5. S1 In silico evaluation of MEK1 Proline124 variants; S2 Correlation of factors and MEK1 mutation status; S3. Predictors of response to BRAF inhibition; S4. Univariate progression-free survival (PFS) according to MEK1 status; S5 Characterisation of melanoma cell Lines.
Supplementary Methods from A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
Authors: Holkova Beata , Supko Jeffrey G. , Ames Matthew M. , Reid Joel M. , Shapiro Geoffrey I. , Perkins Edward Brent , Ramakrishnan Viswanathan , Tombes Mary Beth , Honeycutt Connie , McGovern Renee M. , Kmieciak Maciej , Shrader Ellen , Wellons Martha D. , Sankala Heidi , Doyle Austin , Wright John , Roberts John D. , Grant Steven
Published: April 2023

PDF file - 45K
Supplementary Table 1 from First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
Authors: Basu Bristi , Dean Emma , Puglisi Martina , Greystoke Alastair , Ong Michael , Burke Wendy , Cavallin Maria , Bigley Graham , Womack Christopher , Harrington Elizabeth A. , Green Stephen , Oelmann Elisabeth , de Bono Johann S. , Ranson Malcolm , Banerji Udai
Published: April 2023

Supplementary Table 1. Patient characteristics
Data Supplement from The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer
Authors: Backen Alison , Renehan Andrew G. , Clamp Andrew R. , Berzuini Carlo , Zhou Cong , Oza Amit , Bannoo Selina , Scherer Stefan J. , Banks Rosamonde E. , Dive Caroline , Jayson Gordon C.
Published: April 2023

Supplementary Table S1: Spearman correlations (rho) between biomarkers; Supplementary Table S2: Pre-chemotherapy/bevacizumab concentrations of individual angiogenesis associated factors; Supplementary Table S3: comparisons between biomarker parameters by treatment Arm; Supplementary Table S4: comparisons between biomarker parameters by time since surgery; Supplementary Table S5: Validation of the identified biomarkers in the training dataset using bootstrap resampling technique; Supplementary Table S6: Tumour response by Ang1/Tie2 combination categories by treatment in the training set; Supplementary Table S7: Cox proportional hazard models confirming Ang1 and Tie2 as a joint biomarker in the validation dataset (N = 114)
Supplemental Figures and Tables from A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
Authors: Cooper Todd M. , Cassar Jeannette , Eckroth Elena , Malvar Jemily , Sposto Richard , Gaynon Paul , Chang Bill H. , Gore Lia , August Keith , Pollard Jessica A. , DuBois Steven G. , Silverman Lewis B. , Oesterheld Javier , Gammon Guy , Magoon Daniel , Annesley Colleen , Brown Patrick A.
Published: April 2023

Supplemental Figure 1 and Figure 2 Supplemental Tables 1-5
Supplementary Materials and Methods from Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers
Authors: Lombardi Anne J. , Hoskins Elizabeth E. , Foglesong Grant D. , Wikenheiser-Brokamp Kathryn A. , Wiesmüller Lisa , Hanenberg Helmut , Andreassen Paul R. , Jacobs Allison J. , Olson Susan B. , Keeble Winifred W. , Hays Laura E. , Wells Susanne I.
Published: April 2023

Supplementary Materials and Methods. Details on experimental approaches and reagents that were utilized
Supplementary figure 1 from Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma
Authors: Weed Donald T. , Vella Jennifer L. , Reis Isildinha M. , De la fuente Adriana C. , Gomez Carmen , Sargi Zoukaa , Nazarian Ronen , Califano Joseph , Borrello Ivan , Serafini Paolo
Published: April 2023

Supplementary figure 1. Gating strategy for MDSCs enumeration in the blood
Supplementary Tables from Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors
Authors: Varešlija Damir , McBryan Jean , Fagan Ailís , Redmond Aisling M. , Hao Yuan , Sims Andrew H. , Turnbull Arran , Dixon J.M. , Ó Gaora Peadar , Hudson Lance , Purcell Siobhan , Hill Arnold D.K. , Young Leonie S.
Published: April 2023

Table S1. Cell line authentication. Cell line DNA profiling was carried out using ATCC MCF7 DNA profile as reference. Table S2: List of ChIP and mRNA primers used for DNA and mRNA quantification on the Lightcycler (Roche). Table S3: Patient information for endocrine treated patients. Table S4. Over represented TF binding motifs in 666 ER ChIPseq peaks from LetR cells (using the Universe as background, q-value<0.05) Table S5. Enrichment of TF motifs in Veh, Andro peaks separately. Table S6. Associations of EGR3 with patient clinicopathological variables using Fisher's exact test.
Supplementary Tables 1 - 20 from A Surprising Cross-Species Conservation in the Genomic Landscape of Mouse and Human Oral Cancer Identifies a Transcriptional Signature Predicting Metastatic Disease
Authors: Onken Michael D. , Winkler Ashley E. , Kanchi Krishna-Latha , Chalivendra Varun , Law Jonathan H. , Rickert Charles G. , Kallogjeri Dorina , Judd Nancy P. , Dunn Gavin P. , Piccirillo Jay F. , Lewis James S. , Mardis Elaine R. , Uppaluri Ravindra
Published: April 2023

XLS file - 6534KB, S1 SNVs indolent lines. S2 SNVs aggressive lines. S3 Distribution of nucleotide changes. S4 MOC line mutations have similarity to 32 most common HNSCC TCGA mutations. S5 MOC line conservation with human OSCC drivers and novel mutations. S6 Indels all MOC lines. S7 Comparison of predicted changes between aggressive and indolent lines. S8 MOC line common mutations. S9 Unique aggressive MOC line mutations. S10 Comparison of MOC line mutations with TCGA N0 and N+ mutations. S11 TCGA mutation burden per tumor in N0 and N+ specimens. S12 MOC line and TCGA common mutations. S13 Rate of alterations of aggressive MOC/TCGA N+ mutations from Table S10. S14 Rate of alterations of indolent MOC/TCGA N0 mutations from Table S10. S15 SAM analysis of aggressive versus indolent expression data. S16 Compiled rank metric scores of OCAMP-A genes across three human datasets. S17 Cross tabulation and multivariable analysis of OCAMP-B on MD dataset. S18 Weighted voting classification with OCAMP-B on independent UPENN dataset. S19 SVM output data for training and test sets. S20 OCAMP-A comparison to three published signatures.
Supplementary Table 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
Authors: Oberthuer André , Juraeva Dilafruz , Hero Barbara , Volland Ruth , Sterz Carolina , Schmidt Rene , Faldum Andreas , Kahlert Yvonne , Engesser Anne , Asgharzadeh Shahab , Seeger Robert , Ohira Miki , Nakagawara Akira , Scaruffi Paola , Tonini Gian Paolo , Janoueix-Lerosey Isabelle , Delattre Olivier , Schleiermacher Gudrun , Vandesompele Jo , Speleman Frank , Noguera Rosa , Piqueras Marta , Bénard Jean , Valent Alexander , Avigad Smadar , Yaniv Isaac , Grundy Richard G. , Ortmann Monika , Shao Chunxuan , Schwab Manfred , Eils Roland , Simon Thorsten , Theissen Jessica , Berthold Frank , Westermann Frank , Brors Benedikt , Fischer Matthias
Published: April 2023

Supplementary Table 1. Clinical co-variates for the 709 patients who participated in the study. This supplementary table comprises detailed information on clinical co-variates for all 709 neuroblastoma patients who participated in the study.
Supplementary Data 2 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
Authors: Oberthuer André , Juraeva Dilafruz , Hero Barbara , Volland Ruth , Sterz Carolina , Schmidt Rene , Faldum Andreas , Kahlert Yvonne , Engesser Anne , Asgharzadeh Shahab , Seeger Robert , Ohira Miki , Nakagawara Akira , Scaruffi Paola , Tonini Gian Paolo , Janoueix-Lerosey Isabelle , Delattre Olivier , Schleiermacher Gudrun , Vandesompele Jo , Speleman Frank , Noguera Rosa , Piqueras Marta , Bénard Jean , Valent Alexander , Avigad Smadar , Yaniv Isaac , Grundy Richard G. , Ortmann Monika , Shao Chunxuan , Schwab Manfred , Eils Roland , Simon Thorsten , Theissen Jessica , Berthold Frank , Westermann Frank , Brors Benedikt , Fischer Matthias
Published: April 2023

Supplementary Data 2. This supplementary data comprises the r-algorithm scripts required to perform the both model selection and validation as described in the step-by-step protocol
Supplementary Table 2 from MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research
Authors: Chang Wendy , Brohl Andrew S. , Patidar Rajesh , Sindiri Sivasish , Shern Jack F. , Wei Jun S. , Song Young K. , Yohe Marielle E. , Gryder Berkley , Zhang Shile , Calzone Kathleen A. , Shivaprasad Nityashree , Wen Xinyu , Badgett Thomas C. , Miettinen Markku , Hartman Kip R. , League-Pascual James C. , Trahair Toby N. , Widemann Brigitte C. , Merchant Melinda S. , Kaplan Rosandra N. , Lin Jimmy C. , Khan Javed
Published: April 2023

Tab 1: Patient Demographics at Enrollment. Tab 2: Details of Multiple Samples from Individual Patients , Tab 3: Sample Data of Patients and Sequencing Data of Each Patient Sample, Tab 4: Sample Depth and Coverage, Tab 5: Somatic SNVs in Tumor Samples, Tab 6: Somatic Indels in Tumor Samples, Tab 7: Germline SNVs and Indels in Normal Samples, and Tab 8: Fusion Genes in Defuse, and Tab 9: Fusion Genes in TopHat
Supplementary Table 1 from MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research
Authors: Chang Wendy , Brohl Andrew S. , Patidar Rajesh , Sindiri Sivasish , Shern Jack F. , Wei Jun S. , Song Young K. , Yohe Marielle E. , Gryder Berkley , Zhang Shile , Calzone Kathleen A. , Shivaprasad Nityashree , Wen Xinyu , Badgett Thomas C. , Miettinen Markku , Hartman Kip R. , League-Pascual James C. , Trahair Toby N. , Widemann Brigitte C. , Merchant Melinda S. , Kaplan Rosandra N. , Lin Jimmy C. , Khan Javed
Published: April 2023

American College of Medical Genetics (ACMG) Reportable Criteria and Tab2: NCI-Adult MATCH Criteria for Matching Mutation to Drug
Supplementary Figure 4 from First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
Authors: Sarker Debashis , Ang Joo Ern , Baird Richard , Kristeleit Rebecca , Shah Krunal , Moreno Victor , Clarke Paul A. , Raynaud Florence I. , Levy Gallia , Ware Joseph A. , Mazina Kathryn , Lin Ray , Wu Jenny , Fredrickson Jill , Spoerke Jill M. , Lackner Mark R. , Yan Yibing , Friedman Lori S. , Kaye Stan B. , Derynck Mika K. , Workman Paul , de Bono Johann S.
Published: April 2023

Supplementary Figure 4. Association between severity of treatment-related rash and steady-state exposure (day 15 AUC0-24) to pictilisib. (Gr=Grade).
Supplementary Materials and Methods from Development and Clinical Validation of a Blood Test Based on 29-Gene Expression for Early Detection of Colorectal Cancer
Authors: Ciarloni Laura , Ehrensberger Sahar Hosseinian , Imaizumi Natsuko , Monnier-Benoit Sylvain , Nichita Cristina , Myung Seung-Jae , Kim Joo Sung , Song Si Young , Kim Tae Il , van der Weg Boudewijn , Meier Rémy , Borovicka Jan , Beglinger Christoph , Vallet Cédric , Maerten Philippe , Rüegg Curzio , Dorta Gian
Published: April 2023

Supplementary Materials and Methods contains information on Clinical Sites, Investigators, Ethics Committees, Pathology Board, Recruited Subjects in the Swiss Hospitals, Manufacturers of equipment and reagents and Predictive Algorithm Development.
Supplementary Tables 1 - 4 from Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer
Authors: Julien Sylvia , Merino-Trigo Ana , Lacroix Ludovic , Pocard Marc , Goéré Diane , Mariani Pascale , Landron Sophie , Bigot Ludovic , Nemati Fariba , Dartigues Peggy , Weiswald Louis-Bastien , Lantuas Denis , Morgand Loïc , Pham Emmanuel , Gonin Patrick , Dangles-Marie Virginie , Job Bastien , Dessen Philippe , Bruno Alain , Pierré Alain , De Thé Hugues , Soliman Hany , Nunes Manoel , Lardier Guillaume , Calvet Loreley , Demers Brigitte , Prévost Grégoire , Vrignaud Patricia , Roman-Roman Sergio , Duchamp Olivier , Berthet Cyril
Published: April 2023

PDF file, 129K, Table S1: Description of sequenced exons. Table S2: tumor growth observed in the first engraftment. Table S3: Tumor samples for which development of metastasis has been observed after an engraftment into the cecum. Table S4: Ontology analysis of gene differentially expressed between patient tumors and xenografts.
Supplementary Figure 1 from First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
Authors: Sarker Debashis , Ang Joo Ern , Baird Richard , Kristeleit Rebecca , Shah Krunal , Moreno Victor , Clarke Paul A. , Raynaud Florence I. , Levy Gallia , Ware Joseph A. , Mazina Kathryn , Lin Ray , Wu Jenny , Fredrickson Jill , Spoerke Jill M. , Lackner Mark R. , Yan Yibing , Friedman Lori S. , Kaye Stan B. , Derynck Mika K. , Workman Paul , de Bono Johann S.
Published: April 2023

Supplementary Figure 1. Changes in insulin and glucose levels with pictilisib.
Data Supplement from Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to Smoking History
Authors: Karlsson Anna , Ringnér Markus , Lauss Martin , Botling Johan , Micke Patrick , Planck Maria , Staaf Johan
Published: April 2023

Supplementary Figure S1. Frequency of copy number alterations in lung adenocarcinoma groups defined by patient smoking history and genomic principal component analysis.
Data Supplement from Functional Genetic Approach Identifies MET, HER3, IGF1R, INSR Pathways as Determinants of Lapatinib Unresponsiveness in HER2-Positive Gastric Cancer
Authors: Zhang Zhe , Wang Jiping , Ji Dongmei , Wang Chenchen , Liu Rujiao , Wu Zheng , Liu Lian , Zhu Dan , Chang Jinjia , Geng Ruixuan , Xiong Lei , Fang Qiangyi , Li Jin
Published: April 2023

SUPPLEMENTARY FIGURES LEGENDS
Data Supplement from Functional Genetic Approach Identifies MET, HER3, IGF1R, INSR Pathways as Determinants of Lapatinib Unresponsiveness in HER2-Positive Gastric Cancer
Authors: Zhang Zhe , Wang Jiping , Ji Dongmei , Wang Chenchen , Liu Rujiao , Wu Zheng , Liu Lian , Zhu Dan , Chang Jinjia , Geng Ruixuan , Xiong Lei , Fang Qiangyi , Li Jin
Published: April 2023

Supplementary Figure 1. HER2-positive NCI-N87 Cells Show Lapatinib Responsiveness Compared with HER2-negative Cells
Table legends from Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer
Authors: Burdelski Christoph , Reiswich Viktor , Hube-Magg Claudia , Kluth Martina , Minner Sarah , Koop Christina , Graefen Markus , Heinzer Hans , Tsourlakis Maria Christina , Wittmer Corinna , Huland Hartwig , Simon Ronald , Schlomm Thorsten , Sauter Guido , Steurer Stefan
Published: April 2023

Table legends
Supplementary Table 2 from Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer
Authors: Burdelski Christoph , Reiswich Viktor , Hube-Magg Claudia , Kluth Martina , Minner Sarah , Koop Christina , Graefen Markus , Heinzer Hans , Tsourlakis Maria Christina , Wittmer Corinna , Huland Hartwig , Simon Ronald , Schlomm Thorsten , Sauter Guido , Steurer Stefan
Published: April 2023

Supplementary Table 2. Clinico-pathological association of p62 immunostaining in ERG fusion negative cancers
Data Supplement from GSK-3β–Regulated N-Acetyltransferase 10 Is Involved in Colorectal Cancer Invasion
Authors: Zhang Hong , Hou Wei , Wang Hua-Li , Liu Hai-Jing , Jia Xin-Ying , Zheng Xing-Zheng , Zou Yong-Xin , Li Xin , Hou Lin , McNutt Michael A. , Zhang Bo
Published: April 2023

Supplementary Figure S2. The representative images of E-cadherin and GSK-3β staining in CRCs.
Supplementary table 1 from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
Authors: Sborov Douglas W. , Nuovo Gerard J. , Stiff Andrew , Mace Thomas , Lesinski Gregory B. , Benson Don M. , Efebera Yvonne A. , Rosko Ashley E. , Pichiorri Flavia , Grever Michael R. , Hofmeister Craig C.
Published: April 2023

Supplementary table 1. Selected early phase clinical trials evaluating Reolysin single-agent and combination treatment regimens. Abbreviations: SD = stable disease, PR = partial response, CR = complete response; ER = endoplasmic reticulum.
Supplementary Table S1 from Emerging Treatment Paradigms in Radiation Oncology
Authors: Le Quynh-Thu , Shirato Hiroki , Giaccia Amato J. , Koong Albert C.
Published: April 2023

Supplementary Table S1. Active clinical trials for CHK1,2 inhibitors and WEE1 inhibitors as listed in ClinicalTrials.gov
Supplementary Figure 4 from Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model
Authors: Bai Ren-Yuan , Staedtke Verena , Wanjiku Teresia , Rudek Michelle A. , Joshi Avadhut , Gallia Gary L. , Riggins Gregory J.
Published: April 2023

Supplementary Figure 4. Inhibition of D425 cells by MBZ and elacridar